Types of Kidney Disease: Which Ones Are Being Studied With Stem Cell Therapy?

What This Article Covers

"Kidney disease" is not one condition — it is a family of distinct diseases with different causes and, importantly, very different amounts of stem cell research behind them. This article walks through the major subtypes — diabetic kidney disease, acute kidney injury, lupus nephritis, IgA nephropathy, and polycystic kidney disease — and is honest about which have real human clinical trial data, which have only small or uncontrolled early signals, and which remain confined to animal models. No cell therapy discussed here is FDA-approved for any kidney condition, and this article does not name, rank, or recommend any clinic or provider.

Kidney Disease Is a Spectrum, Not One Disease

Nephrologists generally divide kidney disease by how fast it develops (acute vs. chronic) and what triggers it (metabolic, immune, genetic, or structural). The main categories include chronic kidney disease (CKD) — a gradual, usually irreversible loss of function most often caused by diabetes or high blood pressure, per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); diabetic kidney disease, the single largest cause of CKD and kidney failure worldwide; acute kidney injury (AKI), a sudden, often reversible drop in function tied to surgery, sepsis, or dehydration; lupus nephritis, kidney inflammation from the autoimmune disease lupus; IgA nephropathy and other glomerular (filter-unit) diseases; and polycystic kidney disease (PKD), an inherited disorder in which fluid-filled cysts replace healthy tissue. Stem cell research exists for several of these, but the depth of evidence varies enormously — from a published randomized trial down to rat studies only.

Diabetic Kidney Disease: The Strongest Human Data So Far

Diabetic kidney disease has produced the most rigorous human stem cell trial to date: NEPHSTROM, a randomized, placebo-controlled phase 1b/2a study published in the Journal of the American Society of Nephrology (2023). Adults with type 2 diabetes and progressive CKD received a single IV infusion of allogeneic bone marrow mesenchymal stromal cells (ORBCEL-M). In the first cohort of 16 patients, results were genuinely encouraging: over 18 months, kidney function (eGFR) declined by only about 2.6 mL/min/1.73m² per year with cell therapy versus about 8.7 with placebo (P=0.034) — roughly a three-fold slowing. Still, this was a very small, single-cohort safety-and-signal trial, not a confirmatory phase 3, and one patient developed low-level immune sensitization. A separate meta-analysis of three small randomized trials (86 total participants) found no significant improvement in creatinine or GFR, though urine albumin-to-creatinine ratio improved, concluding that "evidence in patients remains inconclusive." Several new trials are currently recruiting.

Acute Kidney Injury: A Cautionary Result

AKI is an attractive target because the kidney can partially repair itself. But the largest rigorous human trial delivered a sobering result: a phase 2, randomized, double-blind, placebo-controlled trial of allogeneic mesenchymal stem cells (AC607) in patients at risk of AKI after cardiac surgery did not meet its primary endpoint — median time to kidney recovery was 15 days with cell therapy versus 12 with placebo (P=0.32) — and was stopped early for futility. Adverse event rates were similar between groups. This is one of the clearest examples of a kidney cell therapy that looked promising in animals but failed in a well-controlled human trial.

Lupus Nephritis: Promising but Uncontrolled Evidence

Lupus nephritis has produced eye-catching early results. An open-label trial of 81 patients with refractory lupus nephritis (allogeneic bone marrow or umbilical cord MSCs) reported renal remission in 60.5% of patients at 12 months, with average GFR rising from about 58.6 to 69.5 mL/min and no reported transplant-related adverse events. The key caveat: this flagship study was uncontrolled and single-center, so the improvement cannot be cleanly separated from concurrent immunosuppressive therapy, which was reduced but not stopped. Several placebo-controlled trials are registered but not yet reported.

IgA Nephropathy and Other Glomerular Diseases: Early-Stage Only

For IgA nephropathy, one of the most common glomerular diseases, human research exists but remains at the earliest stage. A published Phase 1, open-label, dose-escalation trial protocol tests ADR-001 (autologous adipose-derived regenerative cells) purely for safety and tolerability — not effectiveness. No efficacy results have been published for this or other glomerulonephritis subtypes, making this a research target rather than a demonstrated treatment.

Polycystic Kidney Disease: Preclinical Stage Only

PKD is a genetic, structural disease — cysts destroying kidney architecture — rather than a primarily inflammatory one, and the research reflects that. Published work is limited to animal models, such as long-term stem cell studies in PKD rats, and lab-grown "mini-kidney" organoids used for drug discovery, not cyst repair in patients. There is currently no human clinical trial evidence that stem cells can treat PKD.

Bottom Line

Stem cell research spans kidney disease unevenly. Diabetic kidney disease and lupus nephritis currently have the most encouraging — though still preliminary and small-scale — human signals, including one genuine randomized, placebo-controlled result (NEPHSTROM) showing slowed eGFR decline. Acute kidney injury has been tested rigorously and, in the largest trial to date, did not work. IgA nephropathy and other glomerular diseases remain at the safety-testing stage, and polycystic kidney disease has essentially no human cell-therapy evidence, only animal and lab-dish research. No stem cell product is FDA-approved for any form of kidney disease, and anyone considering a trial should look for ClinicalTrials.gov registration, a control group, and transparent reporting of both benefits and risks.